Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University Hospital, Limoges |
---|---|
Information provided by: | University Hospital, Limoges |
ClinicalTrials.gov Identifier: | NCT00820937 |
The aim of this study is to improve the diagnostic of Lewy body dementia by combining the scintigraphy (SPECT) usig a spécific transporter and magnetic resonance imaging (MRI).
Condition | Intervention |
---|---|
Lewy Body Dementia |
Procedure: Single photon emission computed tomography and Magnetic Resonance Imaging |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Single Group Assignment |
Official Title: | Interest of the Combination of the DaTSCAN Scintigraphy and MRI Scan in the Differential Diagnosis of Lewy Body Dementia From Alzheimer Disease in Patients With Hallucinations |
Enrollment: | 20 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | March 2009 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Lewy body dementia is the second leading cause of dementia in France after degenerative Alzheimer's disease.
However its dignosis is difficult. Its comes in large part from the similarity of symptoms with another close dementia syndrome : the Alzheimer disease
One highlight of the Lewy body dementia process being dopaminergic degeneration, the use of specific radioactive tracers is thought to be the way. The radiotracer that has the greatest advantage for these explorations is currently the DaTSCAN because it binds specifically on the dopamine transporter and can be used in Single photon emission computed tomography (SPECT).
The aim of this study is to improve the performance of imaging in the diagnosis of dementia by combining scintigraphy (SPECT) and magnetic resonance imaging (MRI) in the exploration of the striatal region . The development of this method applied to a population of subjects, with hallucinations and cognitive disorders, should demonstrate the value and complementarity of metabolic images (SPECT) and morphological (MRI) within the differential diagnosis of Lewy body dementia and the Alzheimer disease .
From a methodological point of view, the patient will be included in hospital and will have a clinical diagnosis defined according to the criteria of dementia NINCDS-ADRDA for the Alzheimer disease and Mc-Keith criteria for Lewy body dementia. Their MMSE will be over 18 and they have in common recurrent visual hallucinations.
After the inclusion, two steps must be distinguished, a neuropsychological evaluation stage and an scitigraphy exploration . Before the SPECT , all patients should have an MRI.
Ages Eligible for Study: | 65 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
Pôle de psychiatrie du sujet âgé - CH Esquirol | |
Limoges, France, 87000 | |
Service de Neurologie - CHU de Limoges | |
Limoges, France, 87000 | |
Département de Gérontologie - Chu Limoges | |
Limoges, France, 87000 |
Responsible Party: | CHU Limoges ( Marie SENGELEN ) |
Study ID Numbers: | I04014 |
Study First Received: | December 27, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00820937 History of Changes |
Health Authority: | France: Direction Générale de la Santé |
Lewy Body Dementia Ganglion Cysts Alzheimer Disease Hallucinations Basal Ganglia Diseases Central Nervous System Diseases Neurodegenerative Diseases Lewy Body Disease |
Brain Diseases Cognition Disorders Delirium, Dementia, Amnestic, Cognitive Disorders Movement Disorders Mental Disorders Parkinsonian Disorders Dementia Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Movement Disorders Mental Disorders Basal Ganglia Diseases Nervous System Diseases Central Nervous System Diseases |
Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases Lewy Body Disease Dementia |